IsoTis BV
This article was originally published in Start Up
Executive Summary
Uniting engineering with biology is the aim of IsoTis BV. The start-up has a portfolio of 33 patents all related to what the company terms "substitution medicine", the replacement or repair of human tissue.
You may also be interested in...
Biomaterials: Mechanical Engineering Meets Biology
Start-ups developing man-made surrogates for living processes hope to achieve the alchemy of turning base materials into human tissue.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.